Literature DB >> 25746068

Odds ratio vs risk ratio in randomized controlled trials.

Haribalakrishna Balasubramanian1, Anitha Ananthan, Shripada Rao, Sanjay Patole.   

Abstract

OBJECTIVE: Use of odds ratio (OR) in randomized controlled trials (RCTs) has been criticized because it overestimates the effect size, if incorrectly interpreted as risk ratio (RR). To what extent does this make a difference in the context of clinical research is unclear. We, therefore, aimed to address this issue considering its importance in evidence-based practice of medicine.
METHODS: We reviewed 580 RCTs published in the New England Journal of Medicine between January 2004 and June 2014 and identified 107 RCTs that reported unadjusted RR (n = 76) or OR (n = 31) for the primary outcome. For studies reporting ORs, we calculated RRs, and vice versa, using Stata software. The percentage of divergence between the reported and calculated effect size estimates was analyzed.
RESULTS: None of the RCTs showed a statistically significant result becoming insignificant or vice versa depending on the effect size estimate. OR exaggerated the RR in 62% of the RCTs. The percentage of overestimation was > 50% in 28 RCTs and > 100% in 13 RCTs. The degree of overestimation was positively correlated with the prevalence of outcomes (spearman's rho = 0.84 and 0.66, p < 0.001).
CONCLUSION: Use of OR instead of RR in RCTs does not change the qualitative inference of results. However, the use of OR can markedly exaggerate the effect size in RCTs if misinterpreted as RR and, hence, has the potential to mislead clinicians.

Keywords:  Odds ratio; effect size; randomized controlled trials; risk ratio

Mesh:

Year:  2015        PMID: 25746068     DOI: 10.1080/00325481.2015.1022494

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

1.  Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin.

Authors:  Yonghong Zhang; Da Shi; Ruben Abagyan; Weina Dai; Mingyang Dong
Journal:  Interdiscip Sci       Date:  2019-05-20       Impact factor: 2.233

2.  Bin-CE: A comprehensive web application to decide upon the best set of outcomes to be combined in a binary composite endpoint.

Authors:  Josep Ramon Marsal; Ignacio Ferreira-González; Aida Ribera; Gerard Oristrell; Jose Ignacio Pijoan; David García-Dorado
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

3.  Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials.

Authors:  Jong Yeob Kim; Keum Hwa Lee; Michael Eisenhut; Hans J van der Vliet; Andreas Kronbichler; Gwang Hun Jeong; Jae Il Shin; Gabriele Gamerith
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

4.  Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India".

Authors:  Bharat Krushna Khuntia; Aman Agarwal; Gautam Sharma
Journal:  Complement Ther Med       Date:  2022-04-26       Impact factor: 3.335

Review 5.  Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.

Authors:  Olivia L Tseng; John J Spinelli; Carolyn C Gotay; Wan Y Ho; Mary L McBride; Martin G Dawes
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-03-22       Impact factor: 5.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.